1-bromo-6-(but-3-ynyloxy)hexane | 102294-98-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-bromo-6-(but-3-ynyloxy)hexane
• 英文别名: 4-[(6-bromohexyl)oxy]but-1-yne；1-bromo-6-[(3-butynyl)oxy]hexane；6-bromohexyl but-3-ynyl ether；4-[(6-bromohexyl)oxy]-1-butyne；6-bromohexy [BUT-3-VNYL] ether；6-Bromohexylbut-3-ynyl ether；1-bromo-6-but-3-ynoxyhexane
• CAS: 102294-98-4
• 化学式: C₁₀H₁₇BrO
• 分子量: 233.148
• InChiKey: KZIWFMXWSZGCQH-UHFFFAOYSA-N

物化性质

• 沸点：
  267.1±25.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-bromo-6-(but-3-ynyloxy)hexane 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-(6-{[4-(3-methyl-5-nitrophenyl)-3-butyn-1-yl]oxy}hexyl)-1,3-oxazolidin-2-one
  参考文献：
  名称：

  The discovery of long-acting saligenin β2 adrenergic receptor agonists incorporating a urea group

  摘要：

  A series of novel, potent and selective human beta(2) adrenoceptor agonists incorporating a urea moiety on the terminal right-hand side phenyl ring of (R)-salmeterol is presented. Urea 9j had long duration of action in vitro on guinea pig trachea, and also in vivo similar to that of salmeterol. It had lower oral absorption and bioavailability than salmeterol in both rat and dog. It had a turnover ratio similar to salmeterol, with no evidence for formation of any aniline metabolites in human liver microsomes and hepatocytes. However no crystalline salts suitable for inhaled delivery were identified. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.043
• 作为产物：
  描述：

  1,6-二溴己烷 、 3-丁炔-1-醇 在 四丁基硫酸氢铵 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 72.0h， 以79%的产率得到1-bromo-6-(but-3-ynyloxy)hexane
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Long-acting β₂ Adrenergic Receptor Agonists Incorporating Arylsulfonamide Groups

  摘要：

  A series of saligenin alkoxyalkylphenylsulfonamide beta(2) adrenoceptor agonists were prepared by reacting a protected saligenin oxazolidinone with alkynyloxyalkyl bromides, followed by Sonogashira reaction, hydrogenation, and deprotection. The meta-substituted primary sulfonamide was more potent than the para and the ortho-analogues. Primary sulfonamides were more potent than the secondary and tertiary analogues. The onset and duration of action in vitro of selected compounds was assessed on isolated superfused guinea pig trachea. Sulfonamide 29b had the best profile of potency, selectivity, onset, and duration of action on both guinea pig trachea and human bronchus. Furthermore, 29b was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation. Crystalline salts of 29b were identified that had suitable properties for inhaled administration. A proposed binding mode for 29b to the beta(2)-receptor is presented.

  DOI：

  10.1021/jm801016j

文献信息

• BI-FUNCTIONAL QUINOLINE ANALOGS
  申请人：Baker William R.

  公开号：US20110275622A1

  公开（公告）日：2011-11-10

  Provided are compounds of Formula I: wherein X is: R 1 and R 2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.

  提供的是以下化合物的结构式：其中X是：R1和R2，与它们结合的苯基一起可以形成一个螺环的、融合的杂环环，所有其他变量如本文所定义，以及它们在治疗肺部炎症或支气管痉挛中的应用，以及包含它们的组合物和制备这些化合物的方法。
• [EN] PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DERIVES DE PHENETHANOLAMINE PERMETTANT DE TRAITER DES MALADIES DES VOIES RESPIRATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2004039762A1

  公开（公告）日：2004-05-13

  The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式（I）的新化合物，以及制备它们的方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸道疾病中的应用。
• The discovery of long-acting saligenin β2 adrenergic receptor agonists incorporating hydantoin or uracil rings
  作者：Panayiotis A. Procopiou、Victoria J. Barrett、Nicola J. Bevan、Peter R. Butchers、Richard Conroy、Amanda Emmons、Alison J. Ford、Séverine Jeulin、Brian E. Looker、Gillian E. Lunniss、Valerie S. Morrison、Peter J. Mutch、Rossana Perciaccante、Mark Ruston、Claire E. Smith、Graham Somers

  DOI：10.1016/j.bmc.2011.05.064

  日期：2011.7

  A series of novel, potent and selective human β2 adrenoceptor agonists incorporating a hydantoin or a uracil ring on the right-hand side phenyl ring of (R)-salmeterol is presented. Hydantoin 12a had long duration of action in vitro on guinea pig trachea, and 12 h in guinea pigs in vivo at its EC90 25 μM. It had lower oral absorption than salmeterol in rats, and lower bioavailability than salmeterol

  β的一系列新颖的，有效的和选择性的人2结合的右手侧苯环上的乙内酰脲或尿嘧啶环肾上腺素受体激动剂（[R）-salmeterol被呈现。乙内酰脲12a在体外对豚鼠气管的作用时间长，在豚鼠体内以EC 90 25μM的作用时间为12 h 。它在大鼠中的口服吸收低于沙美特罗，并且在大鼠和狗中的体内生物利用度均低于沙美特罗（分别为2％和5％）。提出了一种改进的测量给予大鼠的类似物的吸收分数的方法，该方法考虑了葡糖醛酸化的分数。化合物12a在人肝微粒体和肝细胞中代谢为活性乙醛酸12m。
• [EN] PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DERIVES DE PHENETHANOLAMINE POUR TRAITER DES MALADIES RESPIRATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2003072539A1

  公开（公告）日：2003-09-04

  The present invention relates to novel compounds of formula (I),to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式（I）的新化合物，涉及其制备方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸道疾病中的应用。
• [EN] PHENETHANOLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DERIVES DE PHENETHANOLAMINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES MALADIES RESPIRATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2004022547A1

  公开（公告）日：2004-03-18

  The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式（I）的新化合物，以及制造它们的方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸道疾病中的应用。